🇺🇸 FDA
Pipeline program

VESLETEPLIRSEN(SRP-5051)

5051-201

Phase 2 small_molecule active

Quick answer

VESLETEPLIRSEN(SRP-5051) for Duchenne Muscular Dystrophy is a Phase 2 program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Sarepta Therapeutics
Indication
Duchenne Muscular Dystrophy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials